Company Filing History:
Years Active: 2023
Title: Bernd Schlereth: Innovator in Multi-Specific T-Cell Engagers
Introduction
Bernd Schlereth is a notable inventor based in Schlieren, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of multi-specific proteins for therapeutic applications.
Latest Patents
Schlereth holds a patent for "DARPin based multi-specific t-cell engagers." This invention relates to recombinant multi-specific proteins that include binding agents with specificity for various targets, such as CD3, CD33, CD123, and CD70. The patent also encompasses nucleic acids encoding these multi-specific proteins, pharmaceutical compositions containing them, and their use in treating or diagnosing diseases, including acute myeloid leukaemia (AML).
Career Highlights
Throughout his career, Bernd Schlereth has been associated with Molecular Partners AG, a company focused on innovative biopharmaceuticals. His work has been instrumental in advancing therapeutic strategies that leverage the immune system to combat cancer.
Collaborations
Schlereth has collaborated with talented individuals such as Nina Reschke and Sebastian Grimm, contributing to the innovative environment at Molecular Partners AG.
Conclusion
Bernd Schlereth's work in the field of multi-specific t-cell engagers exemplifies the potential of biotechnology to address complex medical challenges. His contributions continue to pave the way for advancements in cancer treatment.